ATLCAR.k.28 cells

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameATLCAR.k.28 cells
Drug Alias NameCAR.k.28 cellskappa Chimeric Antigen Receptor and CD28 Endodomain expressing T cellsanti-kappa CAR T-cell therapy (UNC Lineberger Comprehensive Cancer Center)ATLCAR.k.28 T-cell therapy (UNC Lineberger)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionKappa Myeloma antigen modulators
TargetsKappa Myeloma antigen
Therapy Area/IndicationsSplenic marginal zone lymphomaLymphoma, Mantle-CellLymphoma, Follicular +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesUnc Lineberger Comprehensive Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesUnc Lineberger Comprehensive Cancer Center
Inactive CompaniesN/A
Active IndicationsSplenic marginal zone lymphomaLymphoma, Mantle-CellLymphoma, Follicular +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A